Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.82), $0.15 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $7.4 million versus the consensus estimate of $6.73 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.